摘要
目的探讨二甲双胍联合阿卡波糖治疗2型糖尿病(T2DM)患者的临床疗效及安全性。方法选择118例T2DM患者作为研究对象,随机分为观察组(59例)和对照组(59例),对照组患者口服盐酸二甲双胍片治疗,观察组患者口服盐酸二甲双胍片和阿卡波糖片治疗,疗程均为12周。检测两组患者治疗前后空腹血糖(FBG)、餐后2 h血糖(2 h FBG)和糖化血红蛋白(Hb A1c)等指标水平,并记录治疗期间不良反应的发生情况。结果治疗后,两组患者FBG、2 h FBG和Hb A1c水平均低于治疗前,并且观察组患者上述指标水平也低于对照组,差异均有统计学意义(P<0.05);观察组患者不良反应发生率(5例,8.47%)与对照组(4例,6.78%)的差异无统计学意义(P>0.05)。结论二甲双胍与阿卡波糖联合治疗对T2DM患者的疗效更为显著,且安全性较好。
Objective To explore the effect and safety of melbine combined with acarbose in patients with type 2 diabetes（T2DM）.Methods118 patients with T2DM were selected,divided into observation group（59 cases）and control group（59 cases）. The patients in control group were treated with melbine,and the patients in observation group were treated with melbine combined with acarbose. Al patients were treated for 12 weeks. The indexes levels of fasting blood glucose（FBG）,2-hour postprandial blood glucose（2 h FBG）and hemoglobin Alc（HbA1c）in two groups were detected, and the adverse reactions were record in the process of treatment.ResultsThe levels of FBG,2 h FBG and HbA1c in two groups were significantly reduced after treating respectively,and the above indicators in observation group were significantly less than the control group（P〈0.05）. The rate of adverse reaction was not significantly different between observation group（5 cases,8.47%）and control group（4 cases,6.78%）（P〉0.05）. Conclusion The therapy of melbine combined with acarbose was good efficacy and safety for patients with T2DM.
出处
《中国卫生标准管理》
2016年第15期116-118,共3页
China Health Standard Management
